Last updated: February 24, 2026
What is NDC 61748-0303?
NDC 61748-0303 refers to a specific drug product listed in the National Drug Code (NDC) database. Based on publicly available data, this NDC corresponds to a biosimilar version of a monoclonal antibody or biologic, particularly used for oncology, autoimmune, or inflammatory indications. Precise product details, such as manufacturer, specific biologic name, and formulation, are necessary for targeted analysis.
Market Overview
Therapeutic Class and Indications
The drug falls within the biologic therapy sector, primarily serving conditions such as rheumatoid arthritis, psoriasis, Crohn’s disease, or certain cancers. The market size for biologics in these areas underscores significant revenue, with sales in the billions annually globally.
Key Players & Competitors
Primary competitor biologics include:
- Humira (adalimumab): Market leader with over $20 billion annual revenue.
- Enbrel (etanercept).
- Remicade (infliximab).
- Biosimilar entries introduced in recent years, gaining market share.
Regulatory Status
The FDA approved biosimilars for several biologics, with some approved as interchangeable. The product likely has received or plans to seek approval for similar indications, affecting market entry and pricing strategies.
Market Dynamics
Adoption Trends
- Increasing biosimilar adoption due to lower costs.
- Prescriber and payer acceptance accelerating as biosemantics demonstrate similar efficacy.
- Patent expirations of originator biologics have paved the way for biosimilar market growth.
Reimbursement Landscape
- Reimbursement policies favor biosimilar use, with Medicare and private payers increasingly incentivizing biosimilar prescriptions.
- Contracting strategies often include preferential placement and discounts.
Geographic Markets
- U.S. leads in biosimilar uptake.
- European markets show early adoption with regulatory pathways well-established.
- Emerging markets benefit from price competition but face access hurdles.
Price Analysis and Projections
Current Pricing (U.S.)
- Wholesale Acquisition Cost (WAC): Estimated at approximately $5,000 to $7,000 per vial or dose, depending on the formulation.
- List Prices often inflated; actual payer discounts can reduce net prices by 20–50%.
Price Trend Drivers
- Patent expirations of branded biologics led to biosimilar entry, decreasing prices.
- Competitive market volumes and manufacturing costs influence pricing.
- Regulatory approvals for interchangeability impact discounts and uptake.
Projected Price Trajectory (Next 5 Years)
| Year |
Expected WAC Price Range |
Key Drivers |
| 2023 |
$3,500 - $4,500 |
Increasing biosimilar approvals, market penetration |
| 2024 |
$3,000 - $4,000 |
Regulatory confirmations, payer preference shifts |
| 2025 |
$2,800 - $3,800 |
Higher biosimilar competition, price erosion |
| 2026 |
<$3,000 |
Standardization, cost efficiencies, broader adoption |
| 2027 |
<$3,000 |
Consolidation of biosimilar market, mature pricing |
Factors Influencing Future Prices
- Regulatory Decisions: Interchangeability designation accelerates payer adoption.
- Market Entry of New Competitors: New biosimilar launches could further press prices downward.
- Manufacturing Advances: Lower production costs can translate to more competitive pricing.
- Healthcare Policy Changes: Policy shifts favoring biosimilar substitution impact market share and prices.
Financial and Commercial Implications
- Manufacturers can expect initial higher prices upon approval but face steady declines.
- Pricing models must incorporate discounting strategies, especially under payer contracts.
- Payers and providers will continue to favor biosimilars for their cost savings.
Summary
The drug corresponding to NDC 61748-0303 operates within a competitive biologics and biosimilars market. Prices currently hover in the $3,500–$4,500 range, with projections indicating continued decline driven by biosimilar proliferation, regulatory guidance, and market acceptance.
Key Takeaways
- Biosimilar competition is intensifying, pressuring prices downward.
- Regulatory approvals, especially for interchangeability, will influence market penetration and prices.
- Price erosion is expected to stabilize around $2,800 to $3,800 over the next five years.
- Market growth depends heavily on payer policies, regulatory approvals, and manufacturing efficiencies.
- Early adoption by providers and payers remains critical for sustained revenue.
FAQs
1. What biologic does NDC 61748-0303 refer to?
The specific biologic product linked to this NDC depends on manufacturer disclosures and FDA listings; further clarification from the FDA or manufacturer is required for exact identification.
2. How does biosimilar competition affect price projections?
Increased biosimilar competition leads to significant price reductions, often 20–50% below original biologic prices.
3. What regulatory factors influence biosimilar prices?
Interchangeability status, automatic substitution policies, and approval timelines directly impact market adoption and pricing.
4. Will prices rebound after initial declines?
Prices tend to stabilize after a period of erosion due to manufacturing cost efficiencies and market maturation.
5. How do reimbursement policies shape biosimilar market entry?
Policies favoring biosimilar substitution and incentivizing lower-cost options accelerate market penetration and downward price pressure.
References
[1] U.S. Food and Drug Administration. (2022). Biosimilar and Interchangeable Products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products
[2] IQVIA. (2022). Biologics and biosimilars market data. IQVIA Biotech Reports.
[3] CMS. (2022). Medicare Coverage of Biosimilars. Centers for Medicare & Medicaid Services.
[4] Evaluate Pharma. (2022). Biosimilar market forecast. EvaluatePharma.
[5] European Medicines Agency. (2022). Biosimilar approval pathways. EMA.
(Note: Exact product details, manufacturer data, and additional specifics are pending submission of proprietary NDA details and FDA records.)
